GLP-1 peptides: the emerging longevity research

GLP-1 Peptides Beyond Weight Loss: The Emerging Longevity Case

The conversation around GLP-1 receptor agonists like semaglutide, tirzepatide, and retatrutide keeps circling back to weight loss. Fair enough — that’s where the money is. But there’s a quieter, more interesting thread running through the research literature: could these compounds affect how we age?

I’ll say upfront that nobody has proven GLP-1s extend lifespan. What we do have is a growing pile of data from cardiovascular trials, neurodegeneration studies, and metabolic research that points somewhere worth paying attention to.

A Quick Primer on GLP-1

GLP-1 (glucagon-like peptide-1) is a gut hormone that manages insulin secretion, slows gastric emptying, and signals satiety. The synthetic agonists — semaglutide, tirzepatide, retatrutide — mimic this hormone but persist in circulation far longer than the native peptide, which gets chewed up by DPP-4 enzymes within minutes.

That extended half-life is what makes them therapeutically useful. It’s also what has researchers asking: if you keep this pathway active for months or years, what else happens?

Connecting Metabolism and Aging

Aging is, at its core, a metabolic problem. Cells stop dividing. Mitochondria lose efficiency. Chronic low-grade inflammation sets in — what researchers call “inflammaging.” These processes are tightly linked to how the body handles nutrients, and GLP-1 signalling sits right in the middle of that network.

By improving insulin sensitivity and stabilising blood glucose, GLP-1 agonists may indirectly address several hallmarks of aging: deregulated nutrient sensing, mitochondrial dysfunction, and chronic inflammation. That’s the theoretical case, anyway. The clinical data is starting to catch up.

The Cardiovascular Evidence: SELECT Trial

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) was the first large study to show cardiovascular benefit from a GLP-1 agonist in people without diabetes. Over 17,600 patients with obesity and established cardiovascular disease received either semaglutide 2.4 mg weekly or placebo.

The results were clear: a 20% reduction in major adverse cardiac events (cardiovascular death, non-fatal heart attack, non-fatal stroke) over a mean exposure of 33 months. Hazard ratio 0.80 (95% CI 0.72–0.90, p < 0.001). That's a meaningful effect in a population that wasn't diabetic — they were just overweight with heart disease.

What’s interesting for the aging question is that this benefit appeared independent of the degree of weight loss. Prespecified analyses published in The Lancet in 2025 found the cardiovascular protection held across different levels of adiposity change, suggesting semaglutide is doing something beyond just making people lighter.

The Neurodegeneration Question

This is where it gets complicated, and honestly, a bit disappointing.

Novo Nordisk ran two large Phase 3 trials — EVOKE and EVOKE+ — testing oral semaglutide in early-stage symptomatic Alzheimer’s disease. The trials enrolled thousands of patients. The headline result: semaglutide did not outperform placebo on the primary cognitive endpoints.

But the biomarker data told a different story. Plasma high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation, dropped about 30% in the treatment arms of both trials. That’s a substantial anti-inflammatory signal, even if it didn’t translate into cognitive improvement in this population.

Meanwhile, real-world observational data paints a more encouraging picture. A target trial emulation study published in PMC (2025) found that semaglutide use in type 2 diabetes patients was associated with a 40–70% reduction in Alzheimer’s disease risk compared to other antidiabetic medications, including first-generation GLP-1 receptor agonists.

So: the formal Alzheimer’s treatment trial failed, but the prevention signal from observational data is strong. These aren’t contradictory findings — treating established neurodegeneration is a different problem from preventing it. The wider peptide market boom has been driven largely by GLP-1 success, with the therapeutics market projected to reach $300 billion by 2033.

Thoughts from Peter Attia

Peter Attia isn’t quick to jump on trends, which makes his interest in GLP-1s worth noting. On his podcast (The Drive, AMA #81), he argued that by improving how the body handles insulin and glucose, GLP-1 agonists may address some of the foundational metabolic dysfunction that accelerates aging. He also stressed the need for better trial methodologies — moving beyond simple metabolic markers toward epigenetic age clocks and functional aging measures.

What Researchers Are Looking At Now

Tirzepatide and Biological Aging

Tirzepatide is a dual GLP-1/GIP receptor agonist — it hits two incretin pathways instead of one. Beyond its weight loss and glycaemic effects, researchers at the University of Texas Medical Branch launched the Moody Longevity Trial in November 2025: a randomised study of 90 adults aged 55–70 receiving tirzepatide or no drug for 24 weeks, with biological aging measured by DNA methylation clocks.

This is, as far as I can tell, the first dedicated trial asking whether an incretin drug can slow epigenetic aging. The study also tracks cognitive function, physical mobility, and mood. Results are pending, but the fact that it’s happening at all says something about where the field thinks this is heading.

Retatrutide: The Triple Agonist

Retatrutide goes further — it targets GLP-1, GIP, and glucagon receptors simultaneously. The Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023) produced the most dramatic weight loss numbers in the obesity drug space: 24.2% mean body weight reduction at 48 weeks with the 12 mg dose, compared to 2.1% for placebo. That’s roughly 58 pounds of average weight loss in under a year.

The glucagon receptor activation is the novel piece. Glucagon promotes hepatic fat oxidation and energy expenditure — mechanisms that overlap with some of the metabolic pathways implicated in caloric restriction, the one intervention consistently shown to extend lifespan in animal models. Whether retatrutide’s triple agonism translates into aging-relevant benefits beyond weight loss is an open question, but it’s one that several research groups are now actively pursuing.

A separate Phase 2a trial published in Nature Medicine (2024) showed retatrutide significantly reduced liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), which adds another dimension to its metabolic profile.

Where This Leaves Researchers

GLP-1 agonists aren’t longevity drugs. Not yet. But the data accumulating around cardiovascular protection, neuroinflammation reduction, and metabolic improvement touches on enough hallmarks of aging to warrant serious investigation. The recent regulatory shifts around peptides in the US could open new avenues for research access.

The Moody Longevity Trial will be worth watching. So will any follow-up analyses from the EVOKE trials looking at prevention rather than treatment endpoints. And if the Phase 3 retatrutide data matches the Phase 2 results, we’ll have a new class of triple agonists to study in aging contexts.

None of this is settled science. But it’s the kind of early signal that tends to look obvious in hindsight.

Related articles on Amino Research

• The Peptide Boom: Why the Market Is Doubling by 2033
• Epithalon: The Telomere Peptide with 40 Years of Research
• RFK Jr., the FDA, and 14 Peptides: What the Regulatory Shift Means

Sources:

• Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 2023.
• Novo Nordisk. EVOKE and EVOKE+ Phase 3 trial results, 2025.
• Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023.
• University of Texas Medical Branch. “The Moody Longevity Trial: Tirzepatide to Slow Biological Aging.” ClinicalTrials.gov NCT07220473, 2025.
• PMC. “Associations of semaglutide with Alzheimer’s disease-related dementias in patients with type 2 diabetes.” 2025.
• Peter Attia — AMA #81, The Drive podcast.
• Nature Biotechnology — “Are GLP-1s the first longevity drugs?”

All peptides referenced in this article are for laboratory and research use only. Nothing in this article constitutes medical advice.